Liberals put 6-month pause on efforts to lower cost of patented medicines
Global News
Health Canada first announced in 2019 that the Patented Medicine Prices Review Board (PMPRB) would change how it sets a price cap on medicines in Canada.
Health Minister Jean-Yves Duclos has put a six-month pause on new regulations designed to lower the cost of patented medicines in Canada.
Health Canada first announced in 2019 that the Patented Medicine Prices Review Board (PMPRB) would change how it sets a price cap on medicines in Canada in an effort to lower excessively expensive drug costs.
This will be the fourth delay in implementing those changes.
The regulations were supposed to come into force at the beginning of January, but have been pushed back to July 1, 2022.
Duclos said the newest delay will allow the industry, government and other players in the drug distribution system to focus efforts on fighting the pandemic.
“To bring these amendments into force, in the context of a global pandemic, requires preparedness and consultation,” Duclos said in a statement Thursday.
“A delay also allows the government to further engage stakeholders on the application of these amendments within the changing pharmaceutical landscape.”
Health Canada expects the amendments would save Canadians billions of dollars on patented drugs.